FIBROTX is a privately held company founded in November 2005. Our company is providing innovative tools for personalized dermatology and skin care. FibroTx is housed in state-of-the-art laboratory and prototype-manufacturing facilities at the Tallinn Science Park Tehnopol, Estonia. OUR RESEARCH TEAM consists of highly competent and qualified professionals. We have extensive experience in biomarker research and assay development. OUR MISSION is to develop, manufacture and market non-invasive skin diagnostic devices based on proprietary technologies (patents pending): Transdermal Analysis Patch (TAP): A highly versatile research and development tool for multiplex analyses of protein-based biomarkers on skin. TAP is being offered to customers as a fee-for-service skin diagnostic tool. Skin Exploratory Lateral Flow (SELF): A skin diagnostic device for multiplex analyses of biomarkers from skin for specialists and home use.
Looking for a particular FibroTx employee's phone or email?
The FibroTx annual revenue was $5 million in 2026.
Toomas Neuman is the Chief Scientific Officer of FibroTx.
1 people are employed at FibroTx.
The NAICS codes for FibroTx are [54, 541, 5417, 541713, 54171].
The SIC codes for FibroTx are [873, 87].